• Mycophenolic Acid: Dehydrogenase Inhibitor in Immune Assays

  2026-08-06

  Mycophenolic acid is redefining immunometabolism research by enabling precise metabolic modulation during standardized whole-blood stimulation workflows. This article decodes applied protocols, troubleshooting, and the innovative edge of APExBIO’s high-purity compound for robust cytokine profiling.

• Nystatin (Fungicidin): Antifungal Mechanism, Efficacy & Prot

  2026-08-06

  Nystatin (Fungicidin) is a polyene antifungal agent that disrupts fungal cell membranes, exhibiting potent inhibition against multiple Candida species. Its efficacy, solubility, and protocol guidance are well-characterized for research use, but Nystatin is not active against all pathogens and has defined stability and usage limits.

• SERCA Inhibition by BHQ Enhances HSC Mobilization via ER Str

  2026-08-05

  Li et al. (2025) demonstrate that selective inhibition of SERCA using 2,5-di-tert-butylbenzene-1,4-diol (BHQ) induces mild endoplasmic reticulum stress, resulting in robust hematopoietic stem cell (HSC) mobilization in vivo. Their work elucidates a CaMKII-STAT3-CXCR4 pathway as the mechanistic basis, providing a new strategy for improving stem cell transplantation outcomes.

• Acetylspiramycin (Spiramycin B) in Antimicrobial Resistance

  2026-08-05

  Acetylspiramycin (Spiramycin B) stands out for its efficacy against macrolide-resistant pathogens and its dual role in immune modulation. Integrating robust experimental workflows and troubleshooting strategies, this guide translates the latest evidence—including pediatric Mycoplasma pneumoniae resistance trends—into actionable bench protocols.

• Phenacetin in hiPSC-Derived Organoid PK Models: Insights & S

  2026-08-04

  Explore how Phenacetin (N-(4-ethoxyphenyl)acetamide) enables rigorous, translationally relevant pharmacokinetic studies in human pluripotent stem cell-derived intestinal organoids. This thought-leadership article provides mechanistic rationale, protocol guidance, and strategic insights for researchers seeking to bridge the gap between in vitro modeling and clinical application, with context from recent organoid advances and APExBIO’s analytical-grade Phenacetin.

• FOXA1/PUS1/EIF3b Axis Drives Prostate Cancer Bone Metastasis

  2026-08-04

  This study uncovers a novel FOXA1/PUS1/EIF3b signaling axis that promotes prostate cancer bone metastasis through a non-enzymatic stabilization of EIF3b, independent of PUS1’s catalytic activity. The findings highlight new molecular targets and mechanistic insights that could inform future therapeutic strategies for advanced prostate cancer.

• Dual Enzyme-Responsive Zwitterionic Peptides for Cancer Sele

  2026-08-03

  This study introduces a zwitterionic peptide amphiphile engineered for dual enzyme responsiveness, enabling highly selective cancer cell targeting via intralysosomal self-assembly. The approach achieves a remarkable selectivity index and demonstrates tumor regression with minimal toxicity, offering a significant advance for peptide-based chemotherapeutics.

• Silymarin (SKU BA2260): Advanced Milk Thistle Extract for La

  2026-08-03

  This article equips biomedical researchers and lab technicians with scenario-driven, evidence-based guidance for deploying Silymarin (SKU BA2260) in cell-based assays targeting oxidative stress, hepatocellular carcinoma, and antiviral research. Drawing on peer-reviewed chemistry and validated protocols, it details practical solutions to common experimental hurdles, highlights solubility and workflow advantages, and clarifies vendor reliability—positioning Silymarin as a reproducible, reference-grade compound for advanced laboratory applications.

• Functional Genomics Reveal Death Pathways in Drug Response

  2026-08-02

  The referenced study introduces MEDUSA, a simulation-assisted analytic framework that distinguishes between cell growth and death rates to clarify the genetic underpinnings of drug-induced cytotoxicity. This approach advances our understanding of regulated cell death mechanisms and enhances the accuracy of functional genomic screens in drug research.

• Norepinephrine to Angiotensin II Ratio in Vasodilatory Hypot

  2026-08-01

  This article analyzes a post-hoc study of the ARAMIS trial, which establishes a practical conversion ratio between norepinephrine and angiotensin II for patients with vasodilatory hypotension. The findings offer clinicians and researchers new guidance for vasopressor dosing strategies and facilitate standardized reporting in critical care research.

• Rab14 Enhances Parkin-Mediated Mitophagy via TGN-Mitochondri

  2026-07-31

  This study identifies Rab14 as a key promoter of Parkin-dependent mitophagy, revealing its role in mitochondrial protein turnover and morphology through TGN-derived vesicle contact. The findings clarify how Rab14 integrates with established mitophagy pathways, offering new insights into mitochondrial quality control relevant to neurodegeneration and cell metabolism.

• Trifluoperazine 2HCl: Elevating Dopamine D2 Modulation Workf

  2026-07-31

  Trifluoperazine 2HCl empowers researchers with unmatched potency and solubility for dissecting dopamine D2 receptor signaling and host-directed antibacterial mechanisms. This guide translates the latest mechanistic insights into reproducible experimental workflows, troubleshooting tips, and comparative advantages for neuroscience, immunology, and oncology research.

• Deep Learning Reveals Cardiotoxicity in iPSC-Derived Models

  2026-07-30

  This study introduces a scalable, deep learning-driven platform for detecting drug-induced cardiotoxicity using high-content imaging of human iPSC-derived cardiomyocytes. The findings demonstrate improved early-stage risk assessment in drug discovery, highlighting both methodological advances and implications for high-content phenotypic screening.

• LuQi Formula Attenuates Post-MI Remodeling via SPTLC2-Cerami

  2026-07-30

  This study demonstrates that the LuQi Formula, a traditional herbal mixture, mitigates ventricular remodeling after myocardial infarction by downregulating SPTLC2 and suppressing de novo ceramide synthesis. These findings provide mechanistic clarity on the role of sphingolipid metabolism in cardiac repair, offering targets for future cardiovascular intervention.

• Remdesivir (GS-5734): Advanced Mechanistic Insights for Anti

  2026-07-29

  Explore the unique mechanistic depth of Remdesivir (GS-5734) as a coronavirus and filovirus inhibitor. This article reveals how structural virology advances are reshaping antiviral assay design and highlights APExBIO's contribution to translational research.

8177 records 5/546 page Previous Next 12345 下5页 Last page